Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 in Multi-drug Resistant HIV-1
NCT04406727Phase 3Not yet recruiting
- Sponsor
- United BioPharma
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- IgG Antibodies
01
Overview
A Phase 3 trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by United BioPharma. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04406727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406727.